Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.57, along with a high estimate of $51.00 and a low estimate of $10.35. A 38.75% drop is ...
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of ...
Fintel reports that on October 7, 2025, Citigroup maintained coverage of Tandem Diabetes Care (NasdaqGM:TNDM) with a Neutral ...
SAN DIEGO, October 02, 2025--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2025 results ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ ...
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback